Matts Kågedal, PhD is a Senior Scientist/Pharmacometrician at Gententech/Roche. He received his PhD in pharmacokinetics and drug therapy in 2014 from Uppsala University.
He has been working in the pharmaceutical industry since 1997, initially at AstraZeneca in the neuroscience area where his research was focused on developing methods for the analysis of positron emission tomography (PET) data as well as PKPD analyses in the neuroscience and pain areas.
Since 2014, Dr Kågedal has been working at Roche/Genentech, mostly in the oncology and Ophthalmology therapeutic area. At Genentech, his research is focused on methods for improving dose optimization, including how to individualize dose achieve desired outcomes. He has published around 30 papers in the area of PKPD/pharmacometrics, covering various therapeutic areas and methodological approaches. His focus is on the development of pharmacology based PKPD models applying nonlinear mixed effects modeling methodology to inform drug development and drug use.